# US 2025/0144023 A1 · Melflufen dosage regimens for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144023 A1
- Document ID: US20250144023A1
- Status: Published application
- Kind: A1
- Application number: 18/942,039
- Filed: 2024-11-08
- Published: 2025-05-08
- Earliest claimed: 2015-12-01
- Assignees: Oncopeptides Innovation AB
- Applicants: Oncopeptides Innovation AB
- Inventors: Jakob LINDBERG
- Web page: https://patentgrep.com/patent/US20250144023A1

## CPC

- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/223: of alpha-aminoacids
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention providesmelflufen (melphalan flufenamide; L-Melphalanyl-4-fluoro-L-phenylalanine ethyl ester), or a salt thereof, for use in the treatment or prophylaxis of multiple myeloma, wherein a dosage of melflufen (excluding the mass of any salt) is administered as a parenteral dosage at an infusion rate of 1.0 to 1.8 mg/min. Also provided is melflufen, or a salt thereof, for use in the treatment or prophylaxis of a cancer, for example a solid cancer, wherein a dosage of melflufen is administered as a parenteral dosage at an infusion rate less than 0.8 mg/min (for example 0.3 to 1.0 mg/minor for example 0.3 to 0.8 mg/min).

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A method for treating a patient having multiple myeloma comprising administering to the patient on day 1 of a 28-day cycle (a) a 37.5 mg to 42.5 mg parenteral dosage of melflufen at an infusion rate of 1.2 mg to 1.4 mg of melflufen per minute or (b) a parenteral dosage of a melflufen salt in an amount of 37.5 mg to 42.5 mg of melflufen at an infusion rate of 1.2 mg to 1.4 mg of melflufen per minute;
wherein the cycle is repeated one or more times.

### Claim at position 3

23-27. (canceled)

### Claim 28 (depends on 22)

The method of claim 22, wherein the infusion rate is 1.3 mg of melflufen per minute.

### Claim 29 (depends on 22)

The method of claim 22, wherein the dosage of melflufen or melflufen salt is administered over 25 to 35 minutes.

### Claim 30 (depends on 22)

The method of claim 22, which comprises administering (a) a 40 mg dosage of melflufen or (b) a dosage of a melflufen salt in an amount of 40 mg of melflufen.

### Claim 31 (depends on 22)

The method of claim 22, wherein the dosage of melflufen or melflufen salt is administered over around 30 minutes.

### Claim 32 (depends on 22)

The method of claim 22, wherein the dosage of melflufen or melflufen salt is administered as an intravenous infusion.

### Claim 33 (depends on 22)

The method of claim 22, in which the multiple myeloma is relapsed, refractory and/or relapsed refractory multiple myeloma or in which the multiple myeloma is relapsed and/or relapsed refractory to at least lenalidomide.

### Claim 34 (depends on 22)

The method of claim 22, in which said melflufen or melflufen salt is administered simultaneously, sequentially or separately with one or more further therapeutic agent(s).

### Claim 35 (depends on 34)

The method of claim 34, in which said one or more further therapeutic agent(s) comprise dexamethasone.

### Claim 36 (depends on 22)

The method of claim 22, wherein the dosage of melflufen is administered as a pharmaceutical solution comprising a physiologically acceptable solution, and having a volume of 200 ml to 500 ml.

### Claim 37 (depends on 22)

The method of claim 22, wherein the dosage of melflufen or melflufen salt is administered as a pharmaceutical solution and wherein the concentration of melflufen or melflufen salt in the pharmaceutical solution is 1.2 mg/ml or less.

### Claim 38 (depends on 22)

The method of claim 22, wherein the dosage of melflufen or melflufen salt is prepared from a lyophilized pharmaceutical preparation comprising melflufen or the melflufen salt, and optionally sucrose.

### Claim 39 (depends on 22)

The method of claim 22, wherein the cycle is repeated from 2 to 9 times.

### Claim 40 (depends on 36)

The method of claim 36, wherein the dosage of melflufen or melflufen salt is administered as a pharmaceutical solution comprising a physiologically acceptable solution, and having a volume of 350 ml.

### Claim 41 (depends on 22)

The method of claim 22, wherein the dosage of melflufen or melflufen salt is administered as a pharmaceutical solution comprising a physiologically acceptable solution.

### Claim 42 (depends on 41)

The method of claim 41, wherein the physiologically acceptable solution is a glucose solution.

### Claim 43 (depends on 42)

The method of claim 42, wherein the dosage of melflufen or melflufen salt is administered as a pharmaceutical solution and wherein the concentration of melflufen or the melflufen salt in the pharmaceutical solution is 0.2 mg/ml to 1.2 mg/ml.

### Claim 44 (depends on 39)

The method as claimed as claimed in claim 39, wherein the cycle is repeated from 2 to 7 times.

### Claim 45 (depends on 39)

The method of claim 39, wherein the cycle is repeated 4 times.

### Claim 46 (depends on 22)

The method of claim 22, further comprising administering dexamethasone on day 1 of the cycle; and optionally further administering dexamethasone on days 8, 15 and 22 of the cycle.
